OCULAR THERAPEUTIX IN

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

14 نوفمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

13 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer

12 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

06 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

28 أكتوبر 2024 10:00:04 بحسب NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

21 أكتوبر 2024 09:47:37 بحسب NetDania Notify

NetDania - New 12 months High: OCULAR THERAPEUTIX INC. - COMMON STOCK

16 أكتوبر 2024 15:33:40 بحسب NetDania Notify

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

15 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

09 أكتوبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

09 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

25 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at September Retina Meetings

05 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at Two Investor Conferences in September

04 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 أغسطس 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Second Quarter 2024 Results

07 أغسطس 2024 07:10:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

07 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

31 يوليو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

30 يوليو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 يوليو 2024 16:05:00 بحسب Nasdaq GlobeNewswire